Several patient associations (Médecins du Monde, AIDES, the TRT-5 and CHV collectives, etc.) call on the government to adopt a method hitherto unheard of in France, “the automatic license”, in order to authorize manufacturers of generics to be produced at reduced costs latest treatments for hepatitis C.
Over the past two years, the fight against hepatitis C has made significant progress, thanks in particular to the arrival on the market of sofosbuvir (Sovaldi), a direct-acting antiviral (DAA) considered to be revolutionary because it can be cured up to ‘90% of hepatitis C. The only problem, and not the least, the 12-week treatment costs 46,000 euros! And as the state is committed to reimburse it 100%, he decided in return to reserve this treatment only most severely affected patients, those with advanced liver fibrosis.
One in three patients treated in two years
26,000 people meeting these criteria were thus treated in two years, but 50,000 less severe patients would also need these treatments and do not have access to them, according to Yann Mazens, director of SOS hepatitis Federation.
This is why patient associations call on the State to put an end to this inequality of access to care and thus respond to the risks incurred by patients who do not hesitate to obtain drugs on parallel markets, without having no certainty about the quality of the products they buy.
Read also :
Hepatitis C: towards treatment for all patients?
Hepatitis C: should you get tested?
